DRG Market Assessment reports

In the last decade, the biosimilar therapy market has been growing, led mainly by two therapeutic areas: immunology and oncology. It now continues to expand into new fields. To enhance this growth…

Biosimilars of erythropoiesis-stimulating agents (ESAs) entered the European market a decade ago, but the FDA did not approve the first ESA biosimilar—Retacrit—until June 2018; it launched in…

In 2020, sales of branded biologics in ophthalmology reached over $8.50 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2020-2030 forecast period,…

In 2020, sales of branded biologics for respiratory indications reached nearly $1.50 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2020-…

In 2020, sales of insulins at the ex-manufacturer price level exceeded $11 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2020-2030 forecast…

In 2020, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled almost $4.18 billion in the major pharmaceutical markets under study (…

In 2020, sales of branded biologics in immunology exceeded $70 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this…

In 2020, sales of branded MAb biologics in oncology exceeded $30 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $3…

In 2021, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $130 billion in the major pharmaceutical markets under study (United…

In 2021, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $130 billion in the major pharmaceutical markets under study (United…

Payers play a significant role in determining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential…

The biosimilar / follow-on insulin sector of the diabetes therapy market is evolving. Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine…